MedTrace Logo

PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer

NCT03768349 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2025-04-06

No results posted yet for this study

Summary

Imaging and staging of prostate cancer is critical for surgical and treatment planning. In this protocol we will image patients with suspected metastatic prostate cancer using 11C-Choline PET and Gallium-68 labeled HBED-CC PSMA (more commonly called 68Ga-PSMA-11) or F-18 labeled PSMA 1007 in order to demonstrate their utility in detecting prostate cancer.

Conditions

Interventions

DRUG

Ga-68 PSMA11

Ga-68 PSMA11 PET/CT for detection of tumor location

DRUG

F-18 PSMA 1007

F-18 PSMA 1007 PET/CT for detection of tumor location

Sponsors & Collaborators

Principal Investigators

  • Val Lowe, M.D. · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-03
Primary Completion
2021-07-21
Completion
2021-07-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03768349 on ClinicalTrials.gov